MAPT and Parkinson disease: We investigated four plasma biomarkers α-synuclein, T-tau, Aβ-40, and Aβ-42 to distinguish PD patients with cognitive impairment; moreover, clinical evaluations were performed using MMSE, CDR, UPDRS, and 99mTc-TRODAT-1.